Affiliation:
1. Eddii Inc, New York City, NY, USA
Abstract
Achieving optimal glycemic control in children with type 1 diabetes (T1D) is challenging even when wearing a continuous glucose monitor (CGM). We measured the impact of eddii, a gamified real-time app connected to a CGM, on glycemic control. An open label, eight-week randomized controlled trial (RCT) compared glycemic control utilizing the gamified CGM app connected to Dexcom G6 with only Dexcom G6 usage. Children with T1D using Dexcom G6 were enrolled (N=92, ages 5-12 years). Time-in-range (TIR) data were collected four weeks prior to and during the study period. The gamified CGM app utilization effect was measured by difference-in-difference (D-I-D) models. The TIR and time-above-range (TAR) improved among users of the gamified CGM app; 5.38% higher and 5.80% lower than controls ( P = .001 and P = .019, respectively).
Subject
Biomedical Engineering,Bioengineering,Endocrinology, Diabetes and Metabolism,Internal Medicine
Reference16 articles.
1. CGM leader poised for more growth. Abbott. https://www.abbott.com/corpnewsroom/strategy-and-strength/cgm-leader-poised-for-more-growth.html. Accessed 12 September 2023.
2. MedTechDive. Dexcom reports another record year of new customers amid continued demand for G6 device. 2023. https://www.medtechdive.com/news/dexcom-reports-another-record-year-of-new-customers-amid-continued-demand-f/642472/. Accessed 12 September 2023.
3. Continuous Glucose Monitoring and Intensive Treatment of Type 1 Diabetes
4. Effect of Continuous Glucose Monitoring on Hypoglycemia in Type 1 Diabetes